PMID- 23788857
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130624
LR  - 20240318
IS  - 1428-2526 (Print)
IS  - 1897-4309 (Electronic)
IS  - 1428-2526 (Linking)
VI  - 16
IP  - 1
DP  - 2012
TI  - Effective therapeutic management of hepatocellular carcinoma - on the basis of a 
      clinical case.
PG  - 60-3
LID - 10.5114/wo.2012.27339 [doi]
AB  - The prognosis of patients suffering from primary hepatocellular carcinoma (HCC) 
      is unfavourable because the tumour usually develops in cirrhosis-affected liver 
      and is typically not diagnosed until an advanced stage of the disease. The 5-year 
      survival rate for HCC patients in Europe does not exceed 9%. On the basis of a 
      clinical case, the present article discusses the strategy of treatment of HCC 
      patients. Patients with advanced HCC, stage C according to the Barcelona Clinic 
      Liver Cancer (BCLC) staging system, typically receive systemic chemotherapy with 
      sorafenib. The standard management in the treatment of intermediate-stage HCC, 
      i.e. BCLC's stage B, is chemoembolization (TACE). However, repeated TACE sessions 
      activate factors involved in the process of angiogenesis such as 
      hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF), 
      which can render the procedure ineffective. Therefore, there are scientific 
      foundations for combining TACE with antiangiogenic agents such as sorafenib. 
      Results of studies conducted to date indicate that the combination of sorafenib 
      with TACE in patients with BCLC's stage B brings tangible therapeutic effects 
      while being safe. The value of this therapeutic strategy is confirmed by the case 
      described below, in which TACE + sorafenib have induced a partial regression of 
      HCC.
FAU - Omyla-Staszewska, Joanna
AU  - Omyla-Staszewska J
AD  - Department of Oncology and Haematology, Central Clinical Hospital of the Ministry 
      of Internal Affairs and Administration, Warsaw, Poland.
FAU - Deptala, Andrzej
AU  - Deptala A
LA  - eng
PT  - Case Reports
DEP - 20120229
PL  - Poland
TA  - Contemp Oncol (Pozn)
JT  - Contemporary oncology (Poznan, Poland)
JID - 101233223
PMC - PMC3687383
OTO - NOTNLM
OT  - HCC
OT  - TACE
OT  - hepatocellular carcinoma
OT  - sorafenib
EDAT- 2012/01/01 00:00
MHDA- 2012/01/01 00:01
PMCR- 2012/01/01
CRDT- 2013/06/22 06:00
PHST- 2011/09/19 00:00 [received]
PHST- 2011/11/16 00:00 [revised]
PHST- 2011/12/22 00:00 [accepted]
PHST- 2013/06/22 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2012/01/01 00:01 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - 18256 [pii]
AID - 10.5114/wo.2012.27339 [doi]
PST - ppublish
SO  - Contemp Oncol (Pozn). 2012;16(1):60-3. doi: 10.5114/wo.2012.27339. Epub 2012 Feb 
      29.